S.Biomedics Co., Ltd. (KOSDAQ:304360)

South Korea flag South Korea · Delayed Price · Currency is KRW
38,150
-200 (-0.52%)
At close: Feb 27, 2026
59.62%
Market Cap 472.49B
Revenue (ttm) 16.96B
Net Income (ttm) -9.58B
Shares Out 12.39M
EPS (ttm) -810.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 77,148
Average Volume 87,083
Open 38,250
Previous Close 38,350
Day's Range 37,800 - 39,200
52-Week Range 17,930 - 42,600
Beta 1.26
RSI 60.70
Earnings Date Mar 20, 2026

About S.Biomedics

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2005
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 304360
Full Company Profile

Financial Performance

In 2024, S.Biomedics's revenue was 13.73 billion, an increase of 4.77% compared to the previous year's 13.11 billion. Losses were -6.69 billion, -35.17% less than in 2023.

Financial Statements

News

There is no news available yet.